Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

LITS

Lite Strategy Inc

Dec 22 • 04:00PM ET

1.41

-0.02 -1.40 %

Healthcare • Biotechnology • USA • NASD

Peers: IOVA ARQT FATE APLS ENTA KPTI GERN IMMP ONCT

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-1.31	Insider Own	17.79%	Shs Outstand	35.66M	Perf Week	-7.84%
Market Cap	51.87M	Forward P/E	-	EPS next Y	-	Insider Trans	-8.51%	Shs Float	30.24M	Perf Month	-17.06%
Enterprise Value	41.76M	PEG	-	EPS next Q	-	Inst Own	27.59%	Short Float	0.54%	Perf Quarter	-46.39%
Income	-11.58M	P/S	-	EPS this Y	-	Inst Trans	27.85%	Short Ratio	0.23	Perf Half Y	-37.75%
Sales	0.00M	P/B	0.45	EPS next Y	-	ROA	-16.41%	Short Interest	0.16M	Perf YTD	-42.68%
Book/sh	3.15	P/C	5.13	EPS next 5Y	-	ROE	-16.88%	52W High	9.00 -84.33%	Perf Year	-44.05%
Cash/sh	0.27	P/FCF	-	EPS past 3/5Y	37.89% 25.03%	ROIC	-10.31%	52W Low	1.33 6.02%	Perf 3Y	-62.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.45% 7.40%	Perf 5Y	-96.91%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	81.20%	Oper. Margin	-	ATR (14)	0.14	Perf 10Y	-94.14%
Dividend Ex-Date	Nov 16, 2023	Quick Ratio	12.39	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	35.06	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	12.39	EPS Q/Q	89.72%	SMA20	-16.30%	Beta	0.26	Target Price	22.67
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-23.68%	Rel Volume	0.89	Prev Close	1.43
Employees	4	LT Debt/Eq	0.00	Earnings	-	SMA200	-48.39%	Avg Volume	718.23K	Price	1.41
IPO	Dec 18, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	648,694	Change	-1.40%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Downgrade	Laidlaw	Buy → Hold
Mar-25-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$13 → $2
Mar-25-22	Downgrade	Stifel	Buy → Hold	$6 → $2
Mar-25-22	Downgrade	Jefferies	Buy → Hold	$4 → $1
Feb-03-22	Initiated	Jefferies	Buy	$4
Sep-22-20	Initiated	Alliance Global Partners	Buy	$9
May-29-20	Initiated	SunTrust	Buy	$16
Dec-20-18	Initiated	H.C. Wainwright	Buy	$10
Dec-20-18	Initiated	H.C. Wainwright	Buy
Jul-27-18	Upgrade	Stifel	Hold → Buy	$2.50 → $7
Jul-13-18	Initiated	SunTrust	Buy	$12
Apr-18-16	Reiterated	Wedbush	Neutral	$3 → $2
Mar-23-15	Downgrade	ROTH Capital	Buy → Neutral	$14 → $2.50
Dec-18-14	Reiterated	ROTH Capital	Buy	$22 → $14
Oct-16-14	Reiterated	ROTH Capital	Buy	$20 → $22
Jul-08-14	Resumed	Brean Capital	Buy	$16
Oct-22-13	Reiterated	Stifel	Buy	$11 → $15
Apr-15-13	Initiated	Stifel	Buy	$11

Show Previous Ratings

Nov-17-25 09:00AM	Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations (GlobeNewswire) -5.94%
Oct-29-25 09:00AM	Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations (GlobeNewswire) +7.77%
Oct-16-25 04:06PM	Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026 (GlobeNewswire) -13.15%
Sep-10-25 09:00AM	MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker LITS (Business Wire) +10.43%
Aug-28-25 04:23PM	Crypto Treasury Boom Triggers Insider Trading Concerns Fortune Report (Cryptonews) -6.54%
07:00AM	Loading…
07:00AM	Crypto hoarding brings a stock pop for small firmsand in some cases shows patterns of possible insider trading (Fortune)
Aug-25-25 09:47AM	Biotechs Turn to Digital Coins, Crypto to Boost Stock Prices (Bloomberg)
Aug-05-25 10:38AM	MEI Pharma Chooses Not Bitcoin, Not Ethereum, But Litecoin As Treasury Asset (Benzinga)
09:18AM	Litecoin Hits Five-Month High Amid ETF Optimism and $100M MEI Pharma Treasury (decrypt)
08:00AM	MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising (Business Wire)
Jul-22-25 04:35PM	MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange (Business Wire) -9.62%
Jul-20-25 12:35AM	MEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National Exchange (Insider Monkey)
Jul-18-25 12:55PM	GSR Leads $100M Private Placement into Nasdaq-listed MEI Pharma to Launch First Institutional Litecoin Treasury Strategy Alongside Charlie Lee (etf.com) +31.56%
12:41PM	Crypto Market Value Tops $4 Trillion as Stablecoin Bill Passes (Bloomberg)
10:32AM	BC-Most Active Stocks (Associated Press Finance)
09:42AM	Loading…
09:42AM	Litecoin Surges 10%; Will $100M Bet by Nasdaq-Listed Company Fuel a Larger Rally? (CoinDesk)
08:30AM	MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange (Business Wire)
May-13-25 04:05PM	MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position (Business Wire) +6.22%
Mar-26-25 08:00AM	The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors (Business Wire)
Feb-12-25 04:12PM	MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position (Business Wire)
Nov-12-24 04:05PM	MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position (Business Wire)
Sep-19-24 04:01PM	MEI Pharma Reports Fiscal Year End 2024 Cash Position (Business Wire) -5.10%
Aug-12-24 08:30AM	MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives (Business Wire)
Jul-22-24 08:30AM	MEI Pharma to Consider Strategic Alternatives (Business Wire) +21.33%
Jul-01-24 02:18PM	7 Undervalued Biotech Stocks to Buy for Big-Time Returns (InvestorPlace)
May-09-24 10:57PM	MEIP Stock Earnings: MEI Pharma Beats EPS for Q3 2024 (InvestorPlace)
04:02PM	MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights (Business Wire)
Apr-11-24 08:02AM	MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 (Business Wire)
08:00AM	MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin) in Relapsed Metastatic Colorectal Cancer Patients (Business Wire)
Apr-10-24 08:00AM	MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum (Business Wire)
08:00AM	Loading…
Mar-26-24 08:00AM	MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia (Business Wire)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-13-24 06:15PM	MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -5.32%
05:05PM	MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights (Business Wire)
Feb-08-24 06:48AM	Is MEI Pharma (MEIP) Attractively Priced? (Insider Monkey)
Jan-16-24 05:00PM	MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024 (Business Wire) -11.55%
Dec-11-23 12:00PM	MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023 (Business Wire)
Nov-27-23 10:33AM	11 Cheapest Stocks With Biggest Upside (Insider Monkey) +6.61%
Nov-09-23 04:05PM	MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights (Business Wire)
Nov-08-23 08:00AM	MEI Pharma to Present at the Stifel 2023 Healthcare Conference (Business Wire)
Nov-06-23 04:57PM	MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock (Business Wire) +6.57%
Nov-02-23 11:23AM	Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View (Zacks)
09:00AM	MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023 (Business Wire)
Nov-01-23 12:03PM	Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
09:00AM	MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital (Business Wire)
Oct-20-23 11:43AM	BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank (Zacks)
Oct-18-23 11:13AM	Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up (Zacks)
Oct-17-23 05:33PM	MEI Pharma Recommends Stockholders Not to Consent (Business Wire)
11:47AM	Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD (Zacks)
11:30AM	AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review (Zacks)
Oct-16-23 12:53PM	Catalyst (CPRX) Seeks to Increase Maximum Daily Dose for Firdapse (Zacks)
Oct-10-23 10:54AM	Anson and Cable Car Send Letter to MEI Pharma Stockholders (GlobeNewswire)
Oct-02-23 06:00AM	MEI Pharma Adopts Limited-Duration Stockholder Rights Plan (Business Wire)
Sep-29-23 12:00PM	All You Need to Know About MEI Pharma, Inc. (MEIP) Rating Upgrade to Strong Buy (Zacks)
Sep-28-23 05:00PM	MEI Pharma Issues Statement Regarding Anson and Cable Cars Opportunistic Actions (Business Wire)
Sep-27-23 09:28AM	Q4 2023 MEI Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
09:12AM	MEI Pharma, Inc. (NASDAQ:MEIP) Q4 2023 Earnings Call Transcript (Insider Monkey)
Sep-26-23 04:02PM	MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights (Business Wire)
05:03AM	Anson Funds Management LP Acquires Shares in MEI Pharma Inc (GuruFocus.com)
Sep-23-23 05:03AM	Anson Funds Management LP Acquires Additional Shares in MEI Pharma Inc (GuruFocus.com)
Sep-21-23 08:00AM	MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023 (Business Wire) +5.92%
Sep-18-23 08:00AM	MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car (Business Wire)
Sep-05-23 12:17PM	Three execs leave Infinity Pharmaceuticals after failed merger, layoffs (American City Business Journals)
Aug-16-23 08:00AM	MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer (Business Wire)
Jul-26-23 01:47PM	Cambridge biotech cuts most staffers after merger falls apart (American City Business Journals)
Jul-23-23 02:30PM	MEI Pharma Announces Results of Special Meeting of Stockholders (Business Wire)
Jul-19-23 08:00AM	MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction (Business Wire)
Jul-18-23 09:00AM	MEI Pharma Responds to Anson and Cable Car (Business Wire)
Jul-17-23 09:17AM	Anson and Cable Car File Preliminary Consent Materials to Remove Entire Board of Directors at MEI Pharma, Inc. (GlobeNewswire)
08:00AM	MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction (Business Wire)
Jul-13-23 04:05PM	MEI Pharma Postpones Special Meeting of Shareholders (Business Wire) +10.22%
Jul-11-23 08:00AM	MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals (Business Wire)
Jul-07-23 08:00AM	MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals (Business Wire)
Jul-05-23 08:00AM	MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote "FOR" Pending Transaction with Infinity Pharmaceuticals (Business Wire)
Jun-29-23 08:00AM	MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals (Business Wire)
Jun-27-23 05:15PM	MEI Pharma Responds to Anson and Cable Car (Business Wire)
09:20AM	Anson Funds and Cable Car Capital Issue Statement Regarding the Inferior Proposed Transaction between MEI Pharma and Infinity Pharmaceuticals (GlobeNewswire)
Jun-15-23 12:08PM	MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates (Business Wire)
Jun-13-23 08:00AM	MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor (Business Wire)
Jun-02-23 08:00AM	MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor (Business Wire)
Jun-01-23 04:22PM	Anson Funds and Cable Car Capital Issue Statement Regarding MEI Pharmas Rejection of Their Acquisition Proposal (GlobeNewswire)
08:00AM	MEI Pharma Board of Directors Rejects Unsolicited Proposal (Business Wire)
May-30-23 05:40PM	MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal (Business Wire) +6.94%
May-23-23 04:49PM	Clinical Triumph: MEI Pharma's Voruciclib Demonstrates Encouraging Activity in AML Patients (Benzinga)
08:00AM	MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies (Business Wire)
May-11-23 05:35PM	MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights (Business Wire)
May-09-23 08:35AM	Assertio (ASRT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-18-23 03:31PM	Lacklustre Performance Is Driving MEI Pharma, Inc.'s (NASDAQ:MEIP) Low P/S (Simply Wall St.)
Apr-14-23 04:15PM	MEI Pharma Announces 1-for-20 Reverse Stock Split (Business Wire)
Feb-23-23 12:14PM	Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge (Benzinga) -18.64%
07:00AM	MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates (Business Wire)
Feb-17-23 05:12AM	Rainbows and Unicorns: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Just Became A Lot More Optimistic (Simply Wall St.)
Feb-09-23 06:15PM	MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates (Zacks) -7.54% -10.34%
04:05PM	MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights (Business Wire)
Dec-06-22 04:00PM	MEI Pharma Announces Adjournment of Annual Meeting of Stockholders (Business Wire) -33.52% -7.65%
06:24AM	MEI Pharma, Kyowa Kirin Cull Development Of Blood Cancer Drug Outside Japan, Look For Strategic Alternatives (Benzinga)
Dec-05-22 05:01PM	MEI Pharma Initiates Strategic Realignment (Business Wire) -5.74%
05:00PM	MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting (Business Wire)
Nov-20-22 07:17AM	MEI Pharma First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)

Lite Strategy, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its programs include Voruciclib and ME-344. The company was founded on December 1, 2000, and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schornstein Alexander	10% Owner	Dec 18 '25	Sale	1.37	690,611	946,137	3,674,862	Dec 22 04:15 PM
Flynn James P	Director	Dec 19 '25	Buy	1.40	70,000	97,699	100,000	Dec 22 04:00 PM
Flynn James P	Director	Nov 19 '25	Buy	1.88	12,100	22,777	30,000	Nov 20 04:00 PM
Anson Funds Management LP	Former 10% Stockholder	Jul 28 '25	Proposed Sale	6.74	1,093,184	7,368,087		Jul 28 07:20 PM
Funicular Funds, LP	Former member of group that ow	Jul 23 '25	Proposed Sale	6.20	611,440	3,790,928		Jul 23 07:18 PM

Open in Screener

ASMB

Assembly Biosciences Inc

Dec 22 • 04:00PM ET

36.18

+0.92 2.61 %

Healthcare • Biotechnology • USA • NASD

ASMB Assembly Biosciences Inc daily Stock Chart

Peers: GILD ABUS IONS ENTA MDGL NBIX VKTX ADAP OMER LXRX

| Held by: VTI VXF IWC BBC AVSC

Index	-	P/E	-	EPS (ttm)	-4.80	Insider Own	36.93%	Shs Outstand	15.82M	Perf Week	4.57%
Market Cap	572.26M	Forward P/E	-	EPS next Y	-4.04	Insider Trans	0.00%	Shs Float	9.98M	Perf Month	-1.50%
Enterprise Value	342.45M	PEG	-	EPS next Q	-0.86	Inst Own	48.66%	Short Float	12.92%	Perf Quarter	39.21%
Income	-38.55M	P/S	15.39	EPS this Y	43.95%	Inst Trans	31.15%	Short Ratio	9.26	Perf Half Y	110.35%
Sales	37.19M	P/B	3.13	EPS next Y	-7.66%	ROA	-22.66%	Short Interest	1.29M	Perf YTD	129.28%
Book/sh	11.55	P/C	2.46	EPS next 5Y	-	ROE	-36.94%	52W High	39.71 -8.88%	Perf Year	167.80%
Cash/sh	14.70	P/FCF	-	EPS past 3/5Y	42.93% 31.58%	ROIC	-20.85%	52W Low	7.75 366.84%	Perf 3Y	159.91%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	65.83% 12.31%	Gross Margin	99.65%	Volatility	6.31% 5.89%	Perf 5Y	-51.06%
Dividend TTM	-	EV/Sales	9.21	EPS Y/Y TTM	32.79%	Oper. Margin	-116.83%	ATR (14)	2.07	Perf 10Y	-61.54%
Dividend Ex-Date	-	Quick Ratio	4.44	Sales Y/Y TTM	31.30%	Profit Margin	-103.65%	RSI (14)	57.16	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.44	EPS Q/Q	52.10%	SMA20	2.37%	Beta	1.14	Target Price	47.75
Payout	-	Debt/Eq	0.02	Sales Q/Q	57.62%	SMA50	8.80%	Rel Volume	4.45	Prev Close	35.26
Employees	73	LT Debt/Eq	0.01	Earnings	Nov 10 AMC	SMA200	69.99%	Avg Volume	139.27K	Price	36.18
IPO	Dec 17, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.33% 44.64%	Trades		Volume	600,008	Change	2.61%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-25	Initiated	Citizens JMP	Mkt Outperform	$38
Aug-18-25	Resumed	H.C. Wainwright	Buy	$50
Mar-25-25	Initiated	Guggenheim	Buy	$31
Sep-20-24	Upgrade	Jefferies	Hold → Buy	$2 → $35
Sep-13-21	Initiated	H.C. Wainwright	Neutral	$3.50
Sep-02-21	Downgrade	William Blair	Outperform → Mkt Perform
Mar-23-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-06-20	Downgrade	Jefferies	Buy → Hold	$30 → $10
Oct-19-20	Initiated	Truist	Buy	$55
Oct-16-19	Initiated	Mizuho	Buy	$20
Nov-19-18	Initiated	Leerink Partners	Outperform	$45
Oct-08-18	Upgrade	B. Riley FBR	Neutral → Buy	$42
Aug-08-18	Initiated	Robert W. Baird	Outperform	$74
Apr-13-18	Downgrade	Chardan Capital Markets	Buy → Neutral	$35 → $50
Jan-05-18	Initiated	B. Riley FBR, Inc.	Neutral	$35
Nov-08-17	Initiated	Jefferies	Buy	$50
May-30-17	Initiated	Chardan Capital Markets	Buy	$35

Show Previous Ratings

Dec-22-25 08:00AM	Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes (Business Wire)
Dec-08-25 04:05PM	Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes (GlobeNewswire)
Nov-10-25 04:18PM	Assembly Biosciences: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
Nov-07-25 08:00AM	Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting (GlobeNewswire)
05:20PM	Loading…
Nov-04-25 05:20PM	Supernus Pharmaceuticals (SUPN) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-29-25 11:57AM	H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data (Insider Monkey)
Oct-14-25 07:00AM	Assembly Biosciences Announces Upcoming Investor Conference Participation (GlobeNewswire)
Oct-10-25 08:00AM	Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe (GlobeNewswire)
Sep-25-25 09:40AM	Amazon upgraded, Adobe downgraded: Wall Streets top analyst calls (TipRanks)
Sep-24-25 09:36AM	Amazon upgraded, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Sep-22-25 10:32AM	Assembly Biosciences (ASMB) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
Aug-11-25 07:26AM	Assembly Bios herpes drug shows 94% drop in viral shedding (Clinical Trials Arena)
Aug-08-25 08:05AM	Assembly Biosciences Announces Pricing of $175 Million in Equity Financings (GlobeNewswire) +12.96%
08:00AM	Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes (GlobeNewswire)
05:20PM	Loading…
Aug-06-25 05:20PM	Assembly Biosciences: Q2 Earnings Snapshot (Associated Press Finance) +9.21%
04:05PM	Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
04:05PM	Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus (GlobeNewswire)
Jul-26-25 03:00AM	Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop (GlobeNewswire)
Jul-24-25 11:48PM	Assembly Bio's (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial (Insider Monkey)
Jul-02-25 10:09PM	Assembly Biosciences, Inc. (ASMB) Announces Key Leadership and Plan Changes (Insider Monkey)
Jul-01-25 10:50AM	First subject dosed in Assembly Biosciences study for genital herpes (Clinical Trials Arena)
Jun-30-25 08:00AM	Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179 (GlobeNewswire)
Jun-25-25 08:00AM	Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B (GlobeNewswire)
May-27-25 04:05PM	Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference (GlobeNewswire)
May-08-25 05:40PM	Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.04%
04:36PM	Assembly Biosciences: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
May-07-25 05:35PM	Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates (Zacks)
08:00AM	New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025 (GlobeNewswire)
09:47AM	Loading…
May-05-25 09:47AM	Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-29-25 05:35PM	BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.38%
Apr-09-25 02:00AM	Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress (GlobeNewswire)
Apr-08-25 09:35AM	Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround (Zacks)
Mar-26-25 12:00PM	Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -5.34%
Mar-20-25 04:53PM	Assembly Biosciences files for $250 mixed securities shelf (SeekingAlpha)
04:05PM	Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-04-25 08:34PM	Is Assembly Biosciences, Inc. (ASMB) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
Feb-26-25 08:00AM	Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus (GlobeNewswire) +7.86%
Feb-20-25 08:00AM	Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes (GlobeNewswire)
Dec-29-24 03:00AM	Gilead Buys $20.1 Million of Assembly Biosciences Stock (Barrons.com)
Dec-26-24 08:00AM	Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B (GlobeNewswire)
Dec-19-24 08:00AM	Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs (GlobeNewswire) +17.02%
Nov-07-24 06:19PM	Assembly Biosciences: Q3 Earnings Snapshot (Associated Press Finance) +5.11%
04:05PM	Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates (GlobeNewswire)
Sep-23-24 01:39PM	Assembly Biosciences' Investigational Herpes Treatment Shows Safety In Healthy Participants (UPDATED) (Benzinga) -16.31%
08:00AM	Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 (GlobeNewswire)
Sep-16-24 09:40AM	Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-08-24 05:22PM	Assembly Biosciences: Q2 Earnings Snapshot (Associated Press Finance) +6.02%
04:05PM	Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates (GlobeNewswire)
Jul-15-24 08:00AM	Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop (GlobeNewswire)
Jun-18-24 08:00AM	Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection (GlobeNewswire)
Jun-17-24 08:00AM	Assembly Biosciences Announces $12.6 Million in Equity Financings (GlobeNewswire)
Jun-10-24 08:00AM	Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366 (GlobeNewswire) +6.51%
Jun-05-24 08:00AM	Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress 2024 (GlobeNewswire)
May-22-24 08:00AM	Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress 2024 (GlobeNewswire)
May-13-24 08:53AM	ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q1 2024 (InvestorPlace)
May-09-24 05:04AM	Assembly Biosciences: Q1 Earnings Snapshot (Associated Press Finance)
May-08-24 04:05PM	Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-28-24 10:53PM	ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q4 2023 (InvestorPlace)
04:05PM	Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-25-24 12:52PM	ASMB Stock Earnings: Assembly Biosciences Misses EPS for Q2 2023 (InvestorPlace)
Feb-08-24 08:00AM	Assembly Biosciences Announces Effective Date of Reverse Stock Split (GlobeNewswire)
Jan-04-24 08:00AM	Assembly Biosciences Provides Anticipated Development Milestones for 2024 (GlobeNewswire)
Nov-10-23 04:05PM	Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.11%
08:00AM	Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting (GlobeNewswire)
Nov-08-23 05:08PM	Assembly Biosciences: Q3 Earnings Snapshot (Associated Press Finance) -12.48%
04:05PM	Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates (GlobeNewswire)
08:00AM	Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer (GlobeNewswire)
Oct-17-23 10:59AM	Why Is Assembly Biosciences (ASMB) Stock Up 92% Today? (InvestorPlace) +72.18%
07:00AM	Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases (Business Wire)
Oct-11-23 08:00AM	Assembly Biosciences to Present New Data at AASLD The Liver Meeting (GlobeNewswire)
Oct-02-23 08:00AM	Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor (GlobeNewswire)
Sep-19-23 04:05PM	Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting (GlobeNewswire) -5.72%
Aug-09-23 06:11PM	Assembly Biosciences: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates (GlobeNewswire)
Jul-17-23 08:00AM	Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop (GlobeNewswire)
Jun-21-23 08:00AM	Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASLs International Liver Congress 2023 (GlobeNewswire)
Jun-07-23 08:00AM	Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress 2023 (GlobeNewswire)
May-23-23 04:05PM	Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-04-23 06:28PM	Assembly Biosciences: Q1 Earnings Snapshot (AP Finance)
04:05PM	Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Apr-18-23 08:00AM	Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update (GlobeNewswire)
Mar-30-23 10:04AM	Companies Like Assembly Biosciences (NASDAQ:ASMB) Could Be Quite Risky (Simply Wall St.) -10.11%
Mar-22-23 04:05PM	Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights (GlobeNewswire) -8.55%
Feb-15-23 08:00AM	Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes (GlobeNewswire)
Dec-19-22 03:19PM	Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs (Benzinga) +14.53%
08:00AM	Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334 (GlobeNewswire)
Nov-14-22 08:00AM	Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334 (GlobeNewswire) +8.21%
Nov-09-22 09:35AM	After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB) (Zacks)
Nov-08-22 04:05PM	Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation (GlobeNewswire) -7.43%
Nov-04-22 08:00AM	Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV (GlobeNewswire) -5.00%
Oct-24-22 08:00AM	Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting® (GlobeNewswire)
Oct-21-22 09:36AM	Can Assembly Biosciences (NASDAQ:ASMB) Afford To Invest In Growth? (Simply Wall St.)
Oct-05-22 04:05PM	Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor (GlobeNewswire)
Aug-24-22 08:00AM	Assembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases (GlobeNewswire)
Aug-09-22 04:05PM	Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights (GlobeNewswire)
Aug-04-22 12:00PM	Assembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why (Zacks)
10:00AM	Best Momentum Stocks to Buy for August 4th (Zacks)
06:27AM	New Strong Buy Stocks for August 4th (Zacks)

Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McHutchison John G	Director	Mar 31 '25	Sale	9.85	757	7,455	18,347	Apr 15 05:30 PM
Bjorkquist Jeanette M	Principal Accounting Officer	Mar 31 '25	Sale	9.85	180	1,773	4,617	Apr 01 04:05 PM
Okazaki Jason A	CEO and President	Mar 31 '25	Sale	9.85	355	3,496	14,757	Apr 01 04:05 PM
White Nicole S	Chief Manufacturing Officer	Mar 31 '25	Sale	9.85	197	1,940	11,674	Apr 01 04:05 PM
Houghton Michael	Director	Dec 30 '24	Buy	15.61	3,202	49,998	3,202	Dec 31 04:24 PM

LITS

Lite Strategy Inc

ASMB

Assembly Biosciences Inc

Upgrade your FINVIZ experience